Our News

 

Interview Pierre Banzet

CEO Groupe SYNERLAB

By Crystelle Coury, PharmaBoardroom –

(Feb. 2019)

Enjoy your reading!

SERIALIZATION IS UP AND RUNNING!

 

Enjoy your reading!

 

GROUPE SYNERLAB WELCOMES A NEW

GENERAL MANAGER

 

 Enjoy your reading!

UNDERSTANDING  THE CHALLENGES IN DESIGNING & EXECUTING CLINICAL TRIALS FOR SCREENING TESTS!

From Isabelle DECORTE, Head of Pharmaceutical Development & Operations, QP at Synerlab Développement, Orléans

 Enjoy your reading!

OUR NEW EQUIPMENTS

Great visibility of Groupe SYNERLAB in  DOSES 71  dd. May 2018.

Enjoy your reading!

WE ARE SYNERLAB, NICE TO MEET YOU

Glad to let you know more about SYNERLAB

SYNERLAB DÉVELOPPEMENT

INVESTMENTS FOR COMPLEX FORMULATIONS

Specialized in pre-formulation to industrialization pharma development, Synerlab Développement develops oral solid forms by taking into account the regulatory, technical, therapeutic, commercial and insutrial exigencies. In order to adapt to the new formulation challenges posed by the higher number of increasingly complex molecular entities, Synerlab Développement has acquired hot extrusion equipment. This technology improves the bioavailability of active ingredients by adapting its release profile. For the purpose of developing with limited amounts of active ingredients drugs of major therapeutic interest that require quick clinical evaluation, the contract manufacturer has acquired a filling system that allows  the manufacture of low-close capsules of vials.